The Centralized pan-Middle East Survey on the undertreatment of hypercholesterolemia (CEPHEUS) survey evaluated the attainment of low-density lipoprotein cholesterol (LDL-C) goals among patients on lipid-lowering drugs (LLDs) according to the updated National Cholesterol Education Program (NCEP)-Adult Treatment Panel (ATP-III) guideline. The survey was conducted in 6 Arabian Gulf countries. Patients aged ≥18 years on LLDs for at least ≥3 months (stable medication for ≥6 weeks) were recruited. Fasting blood samples were collected at a single visit. In this survey, 5276 (58.2% male) patients were included in the final analysis. The LDL-C goal was attained in 91.1% of low-risk, 52.7% of high-risk, and 32.0% in very-high-risk categories. Goal attainment was directly related to female gender, age <40 years, history of diabetes, and family history of cardiovascular disease. The results of this survey highlight the suboptimal management of hypercholesterolemia across Arabian Gulf countries.
HusseiniAAbu-RmeilehNMMikkiN. Cardiovascular diseases, diabetes mellitus, and cancer in the occupied Palestinian territory. Lancet. 2009;373(9677):1764.
2.
Gehani AbdurrazzakAAl-Hinai AliTZubaidM. Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study [published online November 2, 2012]. Eur J Preventive Cardiol. 2012.
3.
LawMRWaldNJRudnickaAR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.
4.
De BackerGAmbrosioniEBorch-JohnsenK. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24(17):1601–1610.
5.
National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and, management of high blood cholesterol in adults (Adult Management Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and, management of high blood cholesterol in adults (Adult Management Panel III): final report. Circulation. 2002;106(25):3143–3421.
6.
GrundySMCleemanJIMerzCN. National heart, lung, and blood institute; American college of cardiology foundation; American heart association. implications of recent clinical trials for the national cholesterol education program adult management panel III guidelines. Circulation. 2004;110(2):227–239.
7.
EUROASPIRE: A European society of cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J. 1997;18(10):1569–1582.
8.
EUROASPIRE II Study Group Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J. 2001;22(7):554–572.
9.
FordESMokdadAHGilesWHMensahGA. Serum total cholesterol concentrations and awareness, management, and control of hypercholesterolemia among US adults. findings from the national health and nutrition examination survey, 1999 to 2000. Circulation. 2003;107(17):2185–2189.
10.
PearsonTALauroraIChuHKafonekS. The lipid management assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459–467.
11.
FrolkisJPPearceGLNambiVMinorSSprecherDL. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med. 2002;113(8):625–629.
12.
GrahamIAtarDBorch-JohnsenK. European guidelines on cardiovascular disease prevention in clinical practice: executive summa- ry. fourth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2007;28(19):2375–2414.
13.
AlbertiKGEckelRHGrundySM. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and the international association for the study of obesity. Circulation. 2009;120(16):1640–1645.
14.
JavedUDeedwaniaPCBhattDL. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in get with the guidelines (GWTG). Am Heart J. 2010;160(6):1130–1136.
15.
Penning-van BeestFJTermorshuizenFGoettschWGKlungelOHKasteleinJJHeringsRM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J. 2007;28(2):154–159.
16.
GrahamIAtarDBorch-JohnsenKBoysenG. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. fourth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2007;14(suppl 2):E1–E40.
17.
BrookhartMAPatrickARSchneeweissS. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167(8):847–852.
18.
The West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J. 1997;18(11):1718–1724.
19.
BlackburnDFDobsonRTBlackburnJLWilsonTW. Cardiovascular morbidity associated with non-adherence to statin therapy. Pharmacotherapy. 2005;25(8):1035–1043.
20.
RasmussenJNChongAAlterDA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177–186.
21.
The WOSCOPS Study Group. West of scotland coronary prevention study: implications for clinical practice. Eur Heart J. 1996;17(2):163–164.
22.
ShepherdJCobbeSMFordI. For the west of scotland coronary prevention study group. prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301–1307.
23.
SacksFMPfefferMAMoyeLA. For the cholesterol and recurrent events trial investigators. the effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001–1009.
24.
The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4 S). Lancet. 1994;344(8934):1383–1389.
25.
DownsJRClearfieldWeis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615–1622.
26.
SimesRJBakerSMacMahonS. Pravastatin reduces total mortality in patients with coronary heart disease and average cholesterol levels: relationship of baseline cholesterol and treatment effects in the LIPID trials. In: Program and abstracts of the 47th Annual Scientific Session of the American College of Cardiology. Atlanta, GA: Abstract1116; March 29-April 1, 1998.
27.
RidkerPMDanielsonEFonsecaFA. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
28.
HermansMPCastro CabezasMFerrie resJ. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin. 2010;26(2):445–454.
29.
HatzitoliosAIAthyrosVGKaragiannisA. IMPROVE collaborative group. implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. Int J Cardiol. 2009;134(3):322–329.
30.
DaskalopoulouSSDoonanRJMikhailidisDP. Undertreatment of hypercholesterolemia. Curr Med Res Opin. 2010;26(2):439–443.
31.
ParkJEChiangCEMunawarM. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol. 2012;19(4):781–794.
32.
ElisafMSNikasN. Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs—the CEPHEUS-Greece survey. Angiology. 2010;61(5):465–474.
33.
RaalFSchamrothCBlomD. CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia. Cardiovasc J Africa. 2011;22(5):234–240.
34.
WatersDDBrotonsCChiangCW. Lipid treatment assessment project 2 investigators. lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120(1):28–34.
